Founder Evidente. Top rated quantitative analyst, Evidente

Sam Ferraro

Founder Evidente. Top rated quantitative analyst

Evidente

Evidente is an independent financial education firm that delivers innovative financial advice to wholesale investors, including active long only funds, hedge funds, pension funds, and sovereign wealth funds, in Australia and globally.  Drawing on academic research in asset pricing, behavioural finance and portfolio construction, Evidente provides wholesale investors with commercial solutions to stock selection and asset allocation decisions across equities and other asset classes.

Macroeconomics

<span style='font-family: "Calibri",sans-serif; font-size: 14pt; mso-fareast-font-family: "Times New Roman"; mso-ansi-language: EN-AU; mso-fareast-language: EN-AU; mso-bidi-language: AR-SA; mso-bidi-font-family: Helvetica; mso-bidi-font-weight: bold;'>The updated World Economic Outlook reveals that the IMF is (rightly) fed up with the ECB’s timid approach to monetary policy.&nbsp;&nbsp;Monetary policy in the euro area remains slow to respond to the persistent decline in inflation and as a result, the region is vulnerable to any shock that leads to further disinflation or outright deflation.&nbsp; The IMF appears to have adopted the Larry Summers ‘secular stagnation’ view of the post crisis global economy, which draws heavily on the Reinhart/Rogoff interpretation of history; that recoveries from balance sheet recessions are structural and therefore painfully slow.&nbsp; As long as the IMF and other economic forecasters continue to downgrade expectations of global growth, investors should be overweight safe assets and defensive sectors within stock markets, particularly companies that offer sustainably high payout yields, and strong earnings predictability.&nbsp;

The updated World Economic Outlook reveals that the IMF is (rightly) fed up with the ECB’s timid approach to monetary policy.&nbsp;&nbsp;Monetary policy in the euro area remains slow to respond to the persistent decline in inflation and as a result, the region is vulnerable to any shock that leads to further disinflation or outright deflation.&nbsp; The IMF appears to have adopted the Larry Summers ‘secular stagnation’ view of the post crisis global economy, which draws heavily on the Reinhart/Rogoff interpretation of history; that recoveries from balance sheet recessions are structural and therefore painfully slow.&nbsp; As long as the IMF and other economic forecasters continue to downgrade expectations of global growth, investors should be overweight safe assets and defensive sectors within stock markets, particularly companies that offer sustainably high payout yields, and strong earnings predictability.&nbsp; 

The IMF's Patience with the ECB Wears Thin

Macro Strategist, Saxo Capital Markets

Kay Van-Petersen

Macro Strategist

Saxo Capital Markets

Thematic (Sector/Industry)

<ul><li>Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central banker” will soon become mainstream.&nbsp; </li><li>In this piece, KVP takes a snap shot of what happened, the significance &amp; potential ways to look to play things going forward. </li></ul>

Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central banker” will soon become mainstream.&nbsp; In this piece, KVP takes a snap shot of what happened, the significance &amp; potential ways to look to play things going forward. 

Smartkarma AI Primers, Smartkarma

αSK Primers

Smartkarma AI Primers

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

Vertex Pharmaceuticals  / Equity Bottom-Up

<ul>
 <li>
Dominant Market Leader in Cystic Fibrosis: <a href="https://smartkarma.com/entities/vertex-pharmaceuticals-inc-46f344f2-8ae7-441e-b795-e0e6f6c035f1">Vertex Pharmaceuticals </a>commands the cystic fibrosis (CF) market with its portfolio of CFTR modulators, most notably TRIKAFTA/KAFTRIO, which treats approximately 90% of CF patients and accounts for the majority of the company's revenue.</li>
 <li>
Expanding Pipeline Beyond Cystic Fibrosis: The company is actively diversifying its revenue base by investing in a robust pipeline of therapies for other serious diseases, including sickle cell disease, beta-thalassemia, acute and neuropathic pain, type 1 diabetes, and APOL1-mediated kidney diseases.</li>
 <li>
Strong Financial Position and Strategic Growth Initiatives: Vertex maintains a strong balance sheet with significant cash reserves and no debt, enabling continued investment in research and development, strategic acquisitions, and collaborations to fuel future growth.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Dominant Market Leader in Cystic Fibrosis: Vertex Pharmaceuticals commands the cystic fibrosis (CF) market with its portfolio of CFTR modulators, most notably TRIKAFTA/KAFTRIO, which treats approximately 90% of CF patients and accounts for the majority of the company's revenue.
  
Expanding Pipeline Beyond Cystic Fibrosis: The company is actively diversifying its revenue base by investing in a robust pipeline of therapies for other serious diseases, including sickle cell disease, beta-thalassemia, acute and neuropathic pain, type 1 diabetes, and APOL1-mediated kidney diseases.
  
Strong Financial Position and Strategic Growth Initiatives: Vertex maintains a strong balance sheet with significant cash reserves and no debt, enabling continued investment in research and development, strategic acquisitions, and collaborations to fuel future growth.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Vertex Pharmaceuticals  (VRTX UW) - Sep 2025

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Vertex Pharmaceuticals / Equity Bottom-Up

<ul><li>Vertex Pharmaceuticals reported strong performance in the second quarter of 2025, achieving a 12% year-overyear revenue growth, reaching $2.96 billion.</li><li>This growth was driven by the successful commercialization of multiple new products and the expansion of its existing portfolio in treating cystic fibrosis (CF), sickle cell disease, beta thalassemia, and acute pain.</li><li>On the positive side, Vertex Pharmaceuticals made significant strides in the CF market with the introduction of ALYFTREK, which is showing promising adoption across the United States and Europe.</li></ul>

Vertex Pharmaceuticals reported strong performance in the second quarter of 2025, achieving a 12% year-overyear revenue growth, reaching $2.96 billion.This growth was driven by the successful commercialization of multiple new products and the expansion of its existing portfolio in treating cystic fibrosis (CF), sickle cell disease, beta thalassemia, and acute pain.On the positive side, Vertex Pharmaceuticals made significant strides in the CF market with the introduction of ALYFTREK, which is showing promising adoption across the United States and Europe.

Vertex Pharmaceuticals: Will Its Growth of JOURNAVX Be A Critical Breakthrough?

<ul><li>Vertex Pharmaceuticals' latest earnings for the first quarter of 2025 reveals key insights into the company's financial performance and strategic direction.</li><li>The company reported total revenue of $2.77 billion, marking a 3% increase compared to the same period in 2024.</li><li>This growth was primarily driven by strong demand in the U.S., particularly for the cystic fibrosis (CF) treatment ALYFTREK, which gained FDA approval recently.</li></ul>

Vertex Pharmaceuticals' latest earnings for the first quarter of 2025 reveals key insights into the company's financial performance and strategic direction.The company reported total revenue of $2.77 billion, marking a 3% increase compared to the same period in 2024.This growth was primarily driven by strong demand in the U.S., particularly for the cystic fibrosis (CF) treatment ALYFTREK, which gained FDA approval recently.

Vertex Pharmaceuticals: Expansion of CASGEVY & Global Access to Broaden Its Impact & Financial Outcomes!

United States

Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments.  The Company develops drugs for the treatment of cystic fibrosis, autoimmune diseases, cancer, inflammatory bowel disease, and neurological disorders.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Vertex Pharmaceuticals (VRTX US)

The IMF's Patience with the ECB Wears Thin

The updated World Economic Outlook reveals that the IMF is (rightly) fed up with the ECB’s timid approach to monetary policy. Monetary policy in...

Sam Ferraro

Never Trust A Swiss Central Banker

Post SNB surprise announcement yesterday - after leading the market on as recently as a few weeks ago on – the term “Never trust a Swiss central...

Kay Van-Petersen

Primer: Vertex Pharmaceuticals (VRTX UW) - Sep 2025

Dominant Market Leader in Cystic Fibrosis: Vertex Pharmaceuticals commands the cystic fibrosis (CF) market with its portfolio of CFTR...

αSK Primers

Vertex Pharmaceuticals: Will Its Growth of JOURNAVX Be A Critical Breakthrough?

Vertex Pharmaceuticals reported strong performance in the second quarter of 2025, achieving a 12% year-overyear revenue growth, reaching $2.96...

Baptista Research

Vertex Pharmaceuticals: Expansion of CASGEVY & Global Access to Broaden Its Impact & Financial Outcomes!

Vertex Pharmaceuticals' latest earnings for the first quarter of 2025 reveals key insights into the company's financial performance and strategic...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)